Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL524335 | 0.84 | CYP2D6 (0.60) | CYP2D6KDM4E | |
| SCHEMBL24201112 | 0.83 | CYP2D6 (0.45) | CYP2D6KDM4E | |
| SCHEMBL14456599 | 0.81 | CYP2D6 (0.56) | CYP2D6KDM4E | |
| SCHEMBL21659886 | 0.80 | CYP2D6 (0.33) | CYP2D6 | |
| SCHEMBL296447 | 0.79 | — | — | |
| SCHEMBL5432822 | 0.77 | CYP2D6 (0.69) | CYP2D6KDM4E | |
| SCHEMBL1615049 | 0.77 | TSHR (0.39) | — | |
| SCHEMBL831341 | 0.77 | CYP2D6 (0.50) | CYP2D6 | |
| SCHEMBL3639921 | 0.77 | — | — | |
| SCHEMBL7483482 | 0.74 | CYP2D6 (0.47) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023212057-A1 | COMPOSITIONS OF KINETIC NANOPARTICLES CONTAINING NUCLEIC ACIDS, POLYCATIONS AND LIPIDS | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-11-02 | — | — | WO | disclosed |
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2018-04-19 | — | — | US | disclosed |
| US-9719125-B2 | Sampling devices and methods for concentrating microorganisms | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-08-01 | — | — | US | disclosed |
| US-20120003626-A1 | SAMPLING DEVICES AND METHODS FOR CONCENTRATING MICROORGANISMS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | FKBP5, FKBP1B, MALT1 | CYP2D6 162/4885KDM4E 3207/4885 |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | CYP2D6 213/4885KDM4E 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.